KCI shareholders approve buyout; Everist completes Angiologix purchase;

> Kinetic Concepts ($KCI) shareholders have approved the acquisition of the company for $68.50 per common share in cash, or a total value of about $6.3 billion, including outstanding debt. The acquisition is expected to close in early November. KCI release

> Everist Genomics has completed the buy of 100% of the shares of Angiologix, the developer of the AngioDefender diagnostic device for assessing endothelial function. Everist release

> Minister for Jobs, Enterprise and Innovation Richard Bruton is on a 5-day mission in the U.S. to discuss proposals for investment and job creation in Ireland with senior execs from 19 companies. Seven companies he will meet with are in the life sciences sector. Story

> ARKRAY USA's Glucocard Vital and 01 are now listed on the Department of Defense Uniform Formulary. ARKRAY release

> Baxano is expanding its sales infrastructure to meet the rising demand for its products. "We are very optimistic about Baxano's current success and future prospects," said CEO Tony Recupero. "Our monthly sales have grown 300% during the first three quarters of 2011 and Q4 is showing even stronger growth rates." Baxano release

And Finally... A laser powerful enough to tear apart the fabric of space could be built in Britain. In addition to offering insights into undiscovered realms of physics, scientists say the lasers will also produce new treatments for cancer and medical diagnostics. Story

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.